Biotech Stocks on the Move -- Research on CTI BioPharma, BioMarin Pharma, Vertex Pharma, and Northwest Biotherapeutics

LONDON, June 27, 2014 /PRNewswire/ --

On Thursday, June 26, 2014, the NASDAQ Composite ended at 4,379.05, down 0.02%, the Dow Jones Industrial Average declined 0.13%, to finish the day at 16,846.13, and the S&P 500 closed at 1,957.22, down 0.12%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 708.54, up 0.06%, with the index also advancing 5.43% in the previous three months. Investor-Edge has initiated coverage on the following equities: CTI BioPharma Corp. (NASDAQ: CTIC), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and Northwest Biotherapeutics Inc. (NASDAQ: NWBO). Free technical research on CTIC, BMRN, VRTX and NWBO can be downloaded upon signing up at:

http://www.investor-edge.com/4273-register

CTI BioPharma Corp.'s stock finished the Thursday's session 0.34% lower at $2.89. A total of 1.18 million shares were traded, which was below its three months average volume of 2.53 million shares. The stock moved between $2.81 and $2.94 during the session. Although CTI BioPharma Corp.'s shares have lost 1.03% in the previous three trading sessions, it has advanced 1.05% in the last one month and 51.31% on YTD basis. The stock is trading above its 200-day moving average of $2.63, while the 200-day moving average is below CTI BioPharma Corp.'s 50-day moving average of $2.95. CTI BioPharma Corp.'s stock has a Relative Strength Index (RSI) of 44.22. Sign up today to read free research on CTIC at:

http://www.investor-edge.com/4273-CTIC-27Jun2014.pdf

On Thursday, shares in BioMarin Pharmaceutical Inc. fluctuated between $61.31 and $62.94 before ending the session 0.21% higher at $62.69. BioMarin Pharmaceutical Inc.'s stock reported a trading volume of 0.54 million shares, below its three months average volume of 1.61 million shares. Although BioMarin Pharmaceutical Inc.'s shares have surged 11.00% in the last one month, it has declined 2.41% in the previous three trading sessions and 10.89% on YTD basis. The stock is trading above its 50-day moving average of $59.68. Moreover, shares of the company have an RSI of 54.41. Sign up today to read free research on BMRN at:

http://www.investor-edge.com/4273-BMRN-27Jun2014.pdf

On Thursday, Vertex Pharmaceuticals Inc.'s stock gained 3.68%, to close the day at $93.17. The stock recorded a trading volume of 5.51 million shares, much above its three months average volume of 2.03 million shares. The stock oscillated between $88.27 and $93.30 during the session. Over the last three trading sessions and over the past three months, Vertex Pharmaceuticals Inc.'s shares have surged 39.87% and 32.27%, respectively. Additionally, the stock has gained 25.40% since the start of this year. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $72.91 is greater than its 50-day moving average of $69.28. Additionally, the stock has an RSI of 71.77. Sign up today to read free research on VRTX at:

http://www.investor-edge.com/4273-VRTX-27Jun2014.pdf

On Thursday, shares in Northwest Biotherapeutics Inc. recorded a trading volume of 1.36 million shares, higher than its three months average volume of 1.08 million shares. The stock ended the day at $6.78, which was 1.60% below its previous day's closing of $6.89, and registered an intraday range of $6.41 and $7.00. Over the last one month and the previous three months, Northwest Biotherapeutics Inc.'s shares have advanced 16.30% and 0.30%, respectively. Additionally, from the beginning of 2014, the company's stock has gained an upside of 79.84%. The company's stock is trading above its 50-day and 200-day moving averages of $6.21 and $5.20, respectively. Furthermore, shares of the company have an RSI of 50.39. Sign up today to read free research on NWBO at:

http://www.investor-edge.com/4273-NWBO-27Jun2014.pdf

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.investor-edge.com

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED